A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults with Child Pugh A and B Cirrhosis (Liver Disease)
| Sponsor: |
PharmaIN Corporation |
| Enrolling: |
Male and Female Patients |
| Study Length: |
42 Days |
| IRB Number: |
ACYY2024 |
| U.S. Govt. ID: |
NCT05490888 |
| Contact: |
Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu |
Researchers at Columbia University Irving Medical Center are investigating whether PHIN-24 is safe and tolerable after single and multiple ascending doses for people with advanced cirrhosis. Advanced liver cirrhosis is the late stage of chronic liver scarring, where the liver has lost most of its ability to function normally. Study participants will: 1) Be assessed to determine how safe and easy it is to tolerate PHIN-214 when injected for up to 28 days. 2) Be assessed to learn about how their body breaks down and uses PHIN-24. 3) Be assessed to check if their immune system makes antibodies in response to PHIN-214.
Investigator
Giuseppe Cullaro, MD
| Are you 18 years of age and younger than 75 years of age? |
Yes |
No |
| Have you been diagnosed with Cirrhosis? |
Yes |
No |